Replies to post #8128 on Pluristem Therapeutics Inc (PSTI)

[midastouch017]

Indeed very high volume with no news
published is highly irregular for PSTI.
TASE close of equivalent $1.49 is cool!

:-) :-) :-)

[HappyBee]

Scott, it is possible that the Sosei deal has been closed or is near to being closed as in their Quarterly Report (q-10), page 5, Pluristem state:

'In December 2016, we announced that we signed a binding term sheet with Sosei Corporate Venture Capital Ltd., or Sosei CVC, for the establishment of a new Japanese corporation, or NewCo, for the clinical development and commercialization of our PLX-PAD cell therapy product in Japan for CLI. The parties plan to establish NewCo in Japan, in which we will own 35% of the equity in return for our contribution of a perpetual license to commercialize PLX-PAD for CLI in Japan. All proprietary rights related to PLX-PAD will be exclusively owned by us. Sosei CVC's investment fund, Sosei RMF1, together with additional Japanese investors, will raise and invest approximately $11 million, equivalent to approximately ¥1.3 billion, in return for ownership of 65% of NewCo. The parties have agreed to extend the deadline to enter into a definitive agreement until December 31, 2017.'

[EichKing]

Scott, I know I am viewed as negative on here (although I see myself as fairly realistic). With that said, unfortunately the TASE action today will translate to $1.47 tomorrow, and I am skeptical it can finish that high. Tonight's action will tell the tale....up and I'll say I was wrong. Flat, then tomorrow's NASDAQ action will also be flat at best.

Regarding SOSEI, the last slide says finalizing JV is a milestone in the next 12 months. Everything (that hasn't been omitted) in the presentation is could, may, expect....even the "stockpiling" milestone it to advance discussions, not actually purchase anything.....they have never given an idea of when they will commercialize anything....PATHETIC....The most recent dilution simply bought them a little time, this boat is taking on water.